Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Presentation of DCVax-L Results from ASCO by Dr. Keyoumers Ashkan

Here is the link to a video from ASCO in which Dr. Keyoumers Ashkan summarized the results of the phase 3 trial of DCVax-L in newly diagnosed and recurrent glioblastoma. He is the clinical lead for neuro-oncology at King's College Hospital in the UK.and heads the Neuroscience Clinical Trial Unit.  Dr. Ashkan is one of the most respected neurosurgeons in the UK and Kings College is the premier teaching hospital in the UK. He was the chief investigator in the European segment of the phase 3 DCVax-L trial. Needless to say, these are impeccable credentials. Dr. Ashkan believes that DCVax-L is a major therapeutic advance in the treatment of glioblastoma and should become part of standard of care.

The presentation was extremely positive and quite clear. My wife, who does not have a medical background, listened to the presentation with me. Afterwards, I asked her what she took away and I was impressed and pleased that as a lay person, she grasped all the key points.

I am not going to try to summarize Dr. Ashkan's presentation. You should listen for yourself. I would urge Adam Feuerstein to listen to the presentation. On May 10, 2022 after a presentation of this same data at the New York Academy of Sciences, F-stein labeled the trial a failure. His analysis was deeply flawed as I showed in my report:


Northwest Biotherapeutics: Debunking Silly, Fictitious Adam Feuerstein Article Falsely Claiming Phase 3 Trial of DCVax-L in Glioblastoma Multiforme Was a Failure


I will be watching closely to see F-stein's reaction to this presentation. He has portrayed himself as an unbiased, honest  reporter who is quick to correct himself when wrong. If so, he should retract his statement, recognize that the trial was successful and issue a broad apology. Or, will he double down and reiterate that the trial failed ? My bet is on the latter, but we shall see.




Tagged as , + Categorized as Company Reports, LinkedIn


You must be logged in, or you must subscribe to post a comment.